Biotech’s Declaration Of Independence And What Pharma Needs To Do About It
After a long period when only the bravest, well-funded biotechs attempted to build a commercial organization, more companies than ever are taking the go-it-alone plunge. Campbell Alliance thinks we may look back on the commercializing classes of 2011–2012 for key lessons on what drives success, which companies created value and how, and when market challenges prove too much for a new organization.
You may also be interested in...
Ironwood Adds A China Wrinkle To Regional Deal Strategy
The December US launch of linaclotide is a transformative event for Ironwood Pharmaceuticals, the GI drug’s discoverer. But the company’s recent deal with AstraZeneca to sell the drug in China represents another kind of feat and highlights the growing importance of regional deals to Western biotechs.
Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.
Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
In late September, Reata Pharmaceuticals Inc. dealt its Phase IIb chronic kidney disease candidate bardoxolone to Abbott Laboratories Inc., and the $450 million down payment easily dwarfs those on other deals around development-stage drug candidates, going back as far as the eye can see.